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OBJECTIVE—We assessed whether subcutaneous and omental
adipocyte hypertrophy are related to metabolic alterations in-
dependent of body composition and fat distribution in women.
RESEARCH DESIGN AND METHODS—Mean adipocyte di-
ameter of paired subcutaneous and omental adipose tissue
samples was obtained in lean to obese women. Linear regression
models predicting adipocyte size in both adipose tissue depots
were computed using body composition and fat distribution
measures (n = 150). In a given depot, women with larger adipo-
cytes than predicted by the regression were considered as having
adipocyte hypertrophy, whereas women with smaller adipocytes
than predicted were considered as having adipocyte hyperplasia.
RESULTS—Women characterized by omental adipocyte hyper-
trophy had higher plasma and VLDL triglyceride levels as well as
a higher total-to-HDL cholesterol ratio compared with women
characterized by omental adipocyte hyperplasia (P , 0.05). Con-
versely, women characterized by subcutaneous adipocyte hyper-
trophy or hyperplasia showed a similar lipid proﬁle. In logistic
regression analyses, a 10% enlargement of omental adipocytes
increased the risk of hypertriglyceridemia (adjusted odds ratio
[OR] 4.06, P , 0.001) independent of body composition and fat
distribution measures. A 10% increase in visceral adipocyte num-
ber also raised the risk of hypertriglyceridemia (adjusted OR 1.55,
P , 0.02). Associations between adipocyte size and homeostasis
model assessment of insulin resistance were not signiﬁcant once
adjusted for adiposity and body fat distribution.
CONCLUSIONS—Theseresultssuggestthatomental,butnotsub-
cutaneous, adipocyte hypertrophy is associated with an altered
lipid proﬁle independent of body composition and fat distribution
in women. Diabetes 60:1504–1511, 2011
F
at tissue expansion under a positive energy im-
balance relies on adipocyte hypertrophy (en-
largement of existing adipocytes) and adipose
tissue hyperplasia (proliferation and differentia-
tion of preadipocytes) (1,2). Several observational studies
have demonstrated that mean adipocyte sizes in abdomi-
nal subcutaneous and visceral adipose tissue are strongly
associated with body composition and fat distribution
measures (1,3–5). Adiposity and fat cell size are also
intimately related to adipocyte function and to the meta-
bolic alterations associated with obesity. However, factors
other than adiposity and fat distribution seem to inﬂuence
adipocyte size in the subcutaneous and omental adipose
tissue depot (4). For example, Weyer et al. (6) have dem-
onstrated that a signiﬁcant portion of subcutaneous adi-
pocyte size variability is explained by sequence variation in
the lamin A/C gene, even after adjustment for body com-
position. Moreover, changes in adipocyte turnover rates and
extracellular matrix composition may also modulate the
association between adipocyte size and adiposity (6,7).
The large interindividual variability observed in adipocyte
size at a given adiposity level suggests that the proneness to
fat cell hypertrophy in each fat compartment may differ
among individuals. Previous studies have shown that al-
though adiposity and fat distribution are associated with
several metabolic alterations, subcutaneous adipocyte size
remains an independent predictor of these alterations (1,8).
Speciﬁcally, enlarged subcutaneous adipocytes were asso-
ciated with hyperinsulinemia and peripheral insulin re-
sistance independent of adiposity levels (1,5,9–11). More
recently, Arner et al. (1) demonstrated that subcutaneous
adipocyte hypertrophy was linked to low insulin sensitivity
and high insulin levels independent of body composition.
This association may arise from the fact that hypertrophic
adipocytes are more lipolytic, are more resistant to insulin
action than small adipocytes, and have an altered adipo-
kine secretion pattern (12–16).
Although visceral adipose tissue accumulation is known
as an important predictor of metabolic alterations (17,18),
previous studies did not take into account fat distribution
in the association between adipocyte size and measures of
glucose homeostasis or blood lipids (1,5,9–11,19). More-
over, most of these studies could not consider visceral
adipose tissue cellularity (1,5,9,11). The aim of the current
study was, therefore, to assess the impact of interindivid-
ual variation in abdominal subcutaneous and omental ad-
ipocyte size on measures of glucose homeostasis and blood
lipid-lipoprotein levels independent of body composition
and fat distribution in women. We tested the hypothesis
that women characterized by adipocyte hypertrophy in
either omental or subcutaneous fat, but with similar values
of body composition and fat distribution, would be more
likely to present metabolic alterations.
RESEARCH DESIGN AND METHODS
Subjects. The main study sample included 190 women aged 33 to 68 years
recruited through the elective surgery schedule of the Gynecology Unit at the
Laval University Medical Research Center, Québec, Canada. Surgeries were
scheduled for total (n = 184) or subtotal (n = 6) abdominal hysterectomies
sometimes accompanied by a salpingo-oophorectomy of one (n = 27) or two
(n = 71) ovaries. Reasons for surgery included one or more of the following:
myoma (n = 90), menorrhagia/menometrorrhagia (n =8 3 ) ,e n d o m e t r i o s i s( n =
30), ﬁbroids (n = 29), benign cyst (n = 28), incapacitating dysmenorrhea (n =
18), pelvic pain (n = 11), endometrial hyperplasia (n = 8), polyp (n = 7), pelvic
adhesions (n = 5), adenomyosis (n = 3), severe premenstrual syndrome (n =2 ) ,
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ORIGINAL ARTICLEand/or ovarian thecoma (n = 1). Menopausal status determination was based
on follicle-stimulating hormone levels, menstrual history questionnaires, and
medical ﬁles. Thirty-three women were identiﬁed as postmenopausal, whereas
the remaining women were identiﬁed as pre- or peri-menopausal (n = 157).
Twenty-seven women were using hormonal replacement therapy. Severely
obese women (n = 17) undergoing biliopancreatic diversion were recruited at
the Laval University Cardiology and Pulmonology Institute. They were aged 47
years on average, and their BMI ranged from 39.9 to 70.5 kg/m
2. Severe obesity
was deﬁned using the BMI cutoff of the World Health Organization (WHO) (40
kg/m
2). Written informed consent was obtained from all women. The project
was approved by the ethics committees of Laval University Cardiology and
Pulmonology Institute and Laval University Medical Research Center.
Total adiposity and body fat distribution measurements. Within a few
days before or after the surgery, measurements of total adiposity and body fat
distribution were performed in most women (n = 150). Classiﬁcation of normal
weight, overweight, and obese women was performed using BMI cutoff points
of WHO. Total body fat mass and lean body mass were determined using dual-
energy X-ray absorptiometry. Abdominal subcutaneous and visceral adipose
tissue cross-sectional area measures were obtained at the L4-L5 vertebrae
level using a Light Speed 1.1 CT scanner (General Electric Medical Systems,
Milwaukee, WI) (20,21).
Lipid proﬁle and glucose homeostasis. Overnight fasting blood samples
were drawn on the morning of the surgery. Plasma VLDL were isolated by
ultracentrifugation, and the HDL fraction was obtained after precipitation of
LDL in the infranatant with heparin and MnCl2. The HDL2 and HDL3 sub-
fractions were obtained after further precipitation of HDL2 with dextran sul-
fate. Cholesterol and triglyceride levels were measured in plasma and
lipoprotein fractions by enzymatic methods with a Technicon RA-500 analyzer
(Bayer, Etobicoke, Canada) as previously described (22). Apolipoprotein
(apo) B concentrations were measured in plasma, VLDL, or LDL fractions by
the rocket immunoelectrophoretic method of Laurell (20). Glucose was
measured using the glucose oxidase method and insulin was quantiﬁed by
radioimmunoassay (Linco Research, St. Charles, MO). The homeostasis model
assessment of insulin resistance (HOMA-IR) index was calculated using the
following formula: fasting insulin (in mU/mL) 3 fasting glucose (in mmol/L) O
22.5 (23). None of the women recruited from the gynecology unit had a pre-
vious diagnosis of diabetes or took antidiabetic drugs. However, monitoring
fasting plasma glycemia on the morning of surgery revealed that 30 women
had impaired fasting glycemia (.6.1 mmol/L).
Adipose tissue sampling and adipocyte isolation. Within 15 min after the
beginning of the surgical procedure, paired samples of subcutaneous and
omental adipose tissue were respectively collected at the site of surgical in-
cision and the greater omentum. Samples were immediately carried to the
laboratory. A portion of the tissue sample was digested 45 min at 37°C in Krebs-
Ringer-Henseleit buffer supplemented with 350 units/mL of type 1 collagenase
according to a modiﬁed version of the Rodbell method (21,24). Mature
adipocyte suspensions were then washed three times using Krebs-Ringer-
Henseleit buffer.
Adipocyte diameter and number. Mature adipocyte suspension pictures
were acquired using a contrast phase microscope. Mean adipocyte diameter for
each adipose tissue sample was calculated from 250 individual measurements
using Scion Image software (Frederick, MD). Mean adipocyte diameter was
calculated for each distribution. SD and skewness of adipocyte size dis-
tributions were not independently associated to metabolic alterations and were
not included in subsequent analyses. The number of subcutaneous and visceral
adipocytes at the L4-L5 vertebrae level was estimated by dividing abdominal
subcutaneous and visceral adipose tissue area, respectively, by subcutaneous
and omental mean cross-sectional adipocyte surface.
Statistical analyses. Nonlinear curve ﬁt of the association between sub-
cutaneous or omental adipocyte size and BMI was performed usinga one-phase
exponential equation in Prism GraphPad Software. An independent linear
regression analysis was performed to predict adipocyte size in each com-
partment separately using measures of body composition (BMI, fat mass, and
lean body mass) and fat distribution (total, subcutaneous, and visceral adipose
tissue area at L4-L5 vertebrae) as well as age, menopausal status, and hormone
replacement therapy. In models with nonnormally distributed residuals, the
dependent variable was log-transformed. Colinearity among independent
variables was assessed using inﬂation and condition index statistics. Models
were ﬁrst selected based on the Mallows’ Cp statistic and further improved
using the adjusted R
2 and the predicted residual sum of squares (PRESS). For
each model, the study sample was stratiﬁed in two subgroups according to
whether women had a positive (hypertrophy) or negative (hyperplasia) re-
sidual. In each fat depot model, adiposity and metabolic measures between
subgroups were compared using t tests. Variables that were not normally
distributed based on a signiﬁcant Shapiro-Wilk test (P , 0.05) were log10-o r
Box-Cox-transformed.
Two subgroups of 54 women matched for visceral adipose tissue area and
subcutaneous adipocyte size but with either small or large omental adipocytes
were selected. Age and total body fat mass were also carefully matched be-
tween both subgroups. Adiposity and metabolic measures between women
characterized by small or large omental adipocytes were compared using
paired t tests. Multivariate logistic regression analyses were performed to
predict the probability of being characterized by hypertriglyceridemia (.1.69
mmol/L) using measures of adipocyte size and number in each adipose tissue
depot. The model was adjusted for body composition and fat distribution
variables as well as age and menopausal status. Odds ratios (ORs) for each
independent variable were computed for a 10% increase. Statistical analyses
were performed using SAS (SAS Institute).
RESULTS
Subcutaneous and omental adipocyte size was measured
in a sample of 207 lean to severely obese women. The
curve-linear relationship between BMI and adipocyte size
in each depot is shown in Fig. 1. In both fat compartments,
adipocyte size increased along with BMI and tended to
reach a plateau at ;130 mm in severely obese women.
Taken as a whole, omental adipocytes were smaller than
subcutaneous adipocytes but tended to reach similar sizes
in severely obese women (BMI .40 kg/m
2). Subsequent
analyses were performed in lean to moderately obese
women undergoing gynecological surgery, since the re-
lation between adipocyte size and adiposity became non-
linear in severely obese women.
Associations between regional adipocyte size and lipid
proﬁle measures were computed in a subsample of women
for which data on body composition, fat distribution, and
lipid proﬁle were available (n = 150). Characteristics of
these women are shown in Table 1. According to mean
BMI and body composition measures, women were over-
weight but covered a wide range of adiposity values. We
performed linear regression models to predict subcuta-
neous and omental adipocyte sizes using all body compo-
sition and fat distribution variables available (Table 2).
Based on this analysis, lean body mass as well as sub-
cutaneous and visceral adipose tissue area explained 30.8%
of the variance in subcutaneous adipocyte size (model 1).
Lean body mass, BMI, and visceral adipose tissue area
explained 54.3% of the variance in omental adipocyte size
(model 2).
FIG. 1. Subcutaneous and omental adipocyte diameter according to BMI
in women undergoing abdominal gynecologic surgery (n = 190) and
biliopancreatic diversion (n = 17). Women were aged 47.7 6 5.5 years
(range 30–68.3 years) with a mean BMI of 28.5 6 8.8 kg/m
2 (range 17.6–
70.5 kg/m
2). Mean subcutaneous and omental adipocyte sizes were
101.5 6 15.4 mm and 85.2 6 18.6 mm, respectively.
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variance in adipocyte size remained unexplained despite
considering body composition and fat distribution mea-
sures. To assess the impact of adipocyte size variation on
the metabolic proﬁle independent of body composition and
fat distribution, we stratiﬁed the study sample according to
the difference between measured and predicted adipocyte
size in each model. Women with larger adipocytes than
predicted by the regression model (positive residual) were
identiﬁed as hypertrophic, whereas women with smaller
adipocytes than predicted by the model were identiﬁed as
hyperplasic (negative residual) in the corresponding adi-
pose tissue compartment. By design, stratiﬁcations per-
formed using each model generated subgroups of women
characterized by identical body composition and fat distri-
bution values.
Figure 2 shows adipocyte size and number in each adi-
pose tissue compartment according to the presence of hy-
pertrophy or hyperplasia in subcutaneous (left)o ro m e n t a l
(right) adipose tissue. Women characterized by hyper-
trophic subcutaneous adipocytes had fewer but larger
subcutaneous adipocytes than women with hyperplasic
subcutaneous adipocytes (P , 0.0001). Women charac-
terized by subcutaneous adipocyte hypertrophy also had
slightly larger omental adipocytes, but their cell number
remained similar to that of women characterized by sub-
cutaneous adipocyte hyperplasia (P , 0.05). Similarly, larger
but fewer omental adipocytes were observed in women
characterized by omental adipocyte hypertrophy com-
pared with women characterized by omental adipocyte
hyperplasia (P , 0.0001). Although the number of sub-
cutaneous adipocytes was similar in both groups derived
from model 2, slightly larger subcutaneous adipocytes
were observed in women characterized by omental adi-
pocyte hypertrophy (P , 0.05).
No signiﬁcant difference in blood lipids was observed
between women characterized by subcutaneous adipocyte
hypertrophy versus subcutaneous adipocyte hyperplasia
(Fig. 3, left). On the other hand, women characterized
by omental adipocyte hypertrophy had higher levels of
plasma triglycerides, higher VLDL triglycerides, and higher
VLDL cholesterol levels compared with women character-
ized by omental adipocyte hyperplasia (Fig. 3A–C, right).
The ratio of total cholesterol to HDL cholesterol was sig-
niﬁcantly higher in women characterized by omental adi-
pocyte hypertrophy compared with women characterized by
omental adipocyte hyperplasia (Fig. 3D, right). Increased
triglyceride and cholesterol content in the VLDL fraction
may suggest increased particle size (10.89 6 3.85 vs. 9.27 6
3.97 mmol of lipids/g of ApoB, P , 0.01) rather than in-
creased particle number as estimated by VLDL-ApoB
(0.13 6 0.06 vs. 0.12 6 0.07 g/L, NS).
Subdivision of women in three subgroups according to
the SD of the linear regression model residuals generated
results that are comparable with the two-group analyses.
Speciﬁcally, women with adipocyte sizes inside of 1 SD
around the mean showed an intermediate phenotype for
blood lipid levels compared with women above or below 1
SD of the regression residuals (data not shown).
No signiﬁcant difference was observed in fasting glu-
cose (5.75 6 0.65 vs. 5.60 6 0.59, NS) and insulin levels
(10.15 6 5.93 vs. 8.88 6 5.05, NS) as well as in HOMA-IR
index (2.68 6 1.71 vs. 2.34 6 1.60, NS) among women char-
acterized by omental adipocyte hypertrophy or hyperplasia.
Similar results were observed between women characterized
by subcutaneous adipocyte hypertrophy or hyperplasia.
However, when the linear regression analyses were per-
formed using a single measure of total adiposity (i.e., fat
TABLE 1
Physical and metabolic characteristics of the subsample of 150
women
Variables Mean 6 SD
Range
(minimum–maximum)
Anthropometrics
Age (years) 47.1 6 5.1 36.6–68.3
BMI (kg/m
2) 26.7 6 4.8 18.4–39.4
Body fat mass (kg) 26.5 6 9.3 5.8–53.5
Lean body mass (kg) 40.8 6 6.6 25.3–56.4
Adipose tissue area (cm
2)
Total 413 6 163 87–992
Subcutaneous 321 6 131 51–759
Visceral 93 6 46 19–266
Lipid proﬁle (mmol/L)
Plasma triglycerides 1.32 6 0.58 0.47–3.12
VLDL triglycerides 0.80 6 0.49 0.12–2.18
Total cholesterol 5.04 6 0.95 2.62–7.52
VLDL cholesterol 0.47 6 0.30 0.09–1.92
LDL cholesterol 3.13 6 0.86 1.07–5.69
HDL cholesterol 1.44 6 0.36 0.63–2.68
Apolipoprotein B (g/L) 0.95 6 0.25 0.39–1.61
Total-to-HDL cholesterol
ratio 3.70 6 1.13 1.66–9.29
Glucose homeostasis
Fasting glucose
(mmol/L)† 5.67 6 0.63 4.80–8.04
Fasting insulin
(pmol/L)†† 9.5 6 5.5 3.3–27.6
HOMA-IR index††† 2.52 6 1.64 0.72–8.85
Adipocyte diameter (mm)
Subcutaneous 99.7 6 12.8 61.2–130.7
Omental 83.3 6 16.6 44.3–120.5
†n = 138; ††n = 141; †††n = 135.
TABLE 2
Linear regression analyses predicting omental and subcutaneous
adipocyte size in women
Variables*
Partial
(R
2 3 100)
Total
(R
2 3 100)
P
value
Model 1
Dependent
Subcutaneous adipocyte size
Independent
Visceral adipose tissue area 24.6 30.8 ,0.0001
Subcutaneous AT area 4.8 ,0.005
Lean body mass 1.4 0.09
Model 2
Dependent
Omental adipocyte size†
Independent
Visceral adipose tissue area 47.4 54.3 ,0.0001
BMI 3.5 ,0.005
Lean body mass 3.4 ,0.005
*Regression models included BMI, body fat mass, lean body mass,
subcutaneous adipose tissue area, visceral adipose tissue area, age,
menopausal status, and hormone replacement therapy. Models were
selected based on the Mallows’ Cp, adjusted R
2, and PRESS statistics;
colinearity among independent variables was assessed through in-
ﬂation and condition index statistics. †Log-transformed variables;
n 5 150. AT: adipose tissue.
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higher fasting glucose (5.75 6 0.64 vs. 5.57 6 0.59, P =0 . 0 9 ) ,
signiﬁcantly higher fasting insulin levels (10.9 6 6.3 vs. 7.8 6
3.8, P , 0.005), as well as a higher HOMA-IR index (2. 09 6
1.83 vs. 2.00 6 1.16, P , 0.001) in women characterized by
subcutaneous adipocyte hypertrophy compared with women
characterized by subcutaneous adipocyte hyperplasia.
To conﬁrm results of the regression analyses, subgroups
of women matched for fat mass, visceral adipose tissue
area, and subcutaneous adipocyte size but with either
small or large omental adipocytes were compared (Table
3). By design, both subgroups had a similar body compo-
sition and fat distribution. Although subcutaneous adipo-
cyte size and number were comparable, women with large
omental adipocytes had a lower number of visceral adi-
pocytes. Women with large omental adipocytes had higher
levels of plasma triglycerides, of VLDL triglycerides, and of
VLDL cholesterol. A trend for lower HDL cholesterol was
observed in women with large omental adipocytes. The
lower HDL cholesterol value was explained by signiﬁcantly
lower cholesterol content in HDL2, but not in HDL3 lipo-
proteins, in women with larger omental adipocytes. More-
over, the total cholesterol-to-HDL-cholesterol ratio tended
to be higher in women with large omental adipocytes com-
pared with women with small omental adipocytes. Fasting
glucose and insulin concentrations as well as the HOMA-IR
index were similar between women with large versus small
omental adipocytes (Table 3).
The risk of hypertriglyceridemia, deﬁned by triglyceride
levels greater than 1.69 mmol/L in women, was assessed
using logistic regression analyses (Table 4). When adipo-
cyte size and number in each fat depot were included in
the model, the risk of hypertriglyceridemia was associated
with adipose tissue cellularity measures of the visceral, but
not the subcutaneous, fat compartment. Indeed, the risk of
hypertriglyceridemia was signiﬁcantly higher in women
with 10% larger omental adipocytes (OR 2.08 [95% CI 1.48–
3.04]) and with 10% more adipocytes in visceral adipose
tissue (OR 1.16 [1.03–1.30]). After adjustment for BMI,
body fat mass, lean body mass, subcutaneous adipose
tissue area, visceral adipose tissue area, age, and meno-
pausal status, omental adipocyte size (adjusted OR 4.06
[1.92–9.97]) and number (adjusted OR 1.55 [1.12–2.29])
remained independent predictors of hypertriglyceridemia
in women.
DISCUSSION
We designed this study to assess whether subcutaneous
and omental adipose tissue cellularity measures were re-
lated to metabolic alterations independent of body compo-
sition and fat distribution in women. Using linear regression
analyses, women were subdivided in two groups having
lower-than-predicted (hyperplasia) or higher-than-predicted
(hypertrophy) adipocyte sizes in subcutaneous and omen-
tal adipose tissue. Women characterized by omental adi-
pocyte hypertrophy presented a deleterious lipid proﬁle
compared with women characterized by omental adipocyte
hyperplasia. These alterations in the lipid proﬁle were, by
design, independent of differences in body composition and
fat distribution. In contrast, lipid proﬁles were similar
in women characterized by subcutaneous adipocyte hy-
pertrophy versus subcutaneous adipocyte hyperplasia. In
logistic regression analyses including body composition and
FIG. 2. Adipose tissue cellularity in women characterized by hypertrophic or hyperplasic subcutaneous and omental adipocytes. Adipocyte di-
ameter (A) and adipocyte number at the L4-L5 vertebrae level (B) are shown for subcutaneous (SC; model 1; n = 150) and omental (OM; model 2;
n = 150) adipose tissue cellularity stratiﬁcations. Values are mean 6 SEM. *P < 0.05; **P < 0.01.
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largement of omental adipocytes increased the risk of
hypertriglyceridemia by more than fourfold, whereas en-
larged subcutaneous adipocyte size failed to signiﬁcantly
alter the risk of hypertriglyceridemia in women. To a lower
extent, a 10% increase in the number of visceral, but not
subcutaneous, adipocytes multiplied the risk of hyper-
triglyceridemia in women by 1.55-fold. These results sug-
gest that omental fat cell size and number predict lipid
proﬁle alterations independent of body composition and
fat distribution in women. Despite the fact that total and
visceral adiposity are known modulators of the lipid pro-
ﬁl e ,w es h o wh e r ef o rt h eﬁrst time that the extent of
omental adipocyte hypertrophy may inﬂuence this relation.
Previous studies reported that subcutaneous adipocyte
hypertrophy was associated with alterations in glucose
homeostasis (1,5,9–11). Elegant studies from Arner et al.
(1) on adipocyte hypertrophy and adipocyte turnover
showed that individuals characterized by larger sub-
cutaneous adipocytes had higher fasting insulin levels and
HOMA-IR index. In the current study, all measures of body
composition and fat distribution as well as age and men-
opausal status were used to prepare fully adjusted pre-
dictive models for subcutaneous and omental adipocyte
size. Using these models, we failed to observe alterations
in glucose homeostasis measures in women characterized
by adipocyte hypertrophy in subcutaneous or omental
adipose tissue. On the other hand, linear regression anal-
yses predicting adipocyte size performed using only one
measure of total adiposity (e.g., fat mass) revealed glucose
homeostasis alterations in women characterized by sub-
cutaneous adipocyte hypertrophy compared with women
characterized by subcutaneous adipocyte hyperplasia. These
results suggest that associations of glucose homeostasis
FIG. 3. Lipid proﬁle in women characterized by hypertrophic or hyperplasic subcutaneous (model 1; n = 150) and omental (model 2; n = 150)
adipocytes. Overnight fast values of plasma triglyceride (A) (mmol/L), VLDL triglyceride (B) (mmol/L), VLDL cholesterol (C) (mmol/L), and total-
to-HDL cholesterol (D) are shown. Values are mean 6 SEM. *P < 0.05; **P < 0.01.
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others (1,5,9–11), may arise from differences in abdominal
fat distribution rather than differences in subcutaneous
adipose tissue cellularity. Lack of statistical adjustment for
fat distribution measures in previous studies may explain
discrepancies regarding glucose homeostasis alterations in
women characterized by hypertrophic subcutaneous adi-
pocytes (1,5,9–11).
To our knowledge, we are the ﬁrst to report an in-
dependent association between omental adipocyte hyper-
trophy and alterations of the lipid proﬁle in women. With
the exception of two studies (10,19), most authors assessed
the association between adipocyte size and metabolic
parameters using only measures from subcutaneous adi-
pose tissue (1,3,5,11). These studies reported that enlarged
subcutaneous adipocytes were associated with insulin re-
sistance independent of obesity itself (1,5,11). In contrast,
Mundi et al. (3) observed that insulin and triglyceride
levels were slightly better predicted by body composition
measures than subcutaneous adipocyte size. Therefore,
they dismissed the individual effect of subcutaneous adi-
pocyte size on metabolic parameters in men and women
(3). Subcutaneous and omental adipocyte size measures
are closely related (4,25), and part of the effect of omental
adipocyte hypertrophy may be indirectly related to sub-
cutaneous adipocyte size. However, lack of visceral adi-
pocyte size measures in most of these studies may explain
discrepancies observed between our analysis and previous
literature (1,3,5).
We corroborate reports showing that body composition
and fat distribution measures largely predict subcutaneous
and omental adipocyte size (4). However, after adjustment
for all anthropometric measures available, interindividual
variability observed in subcutaneous and omental adipose
tissue was not completely explained. This observation is
consistent with the hypothesis that adipocyte size is reg-
ulated by factors that are independent of variations in
body composition and fat distribution (4). Bergman et al.
(26) suggested that fat accumulation occurs primarily in
the visceral adipose tissue depot and fat storage then spills
over in the subcutaneous adipose tissue depot, whereas
others have proposed that subcutaneous fat is a primary
compartment (27,28). In any case, lipid uptake and lipolysis
rates in each fat depot appear as dynamic processes. Drolet
et al. (2) observed that hyperplasia is predominant in the
subcutaneous adipose tissue, whereas adipocyte hypertro-
phy is present in both adipose tissue depots. Because less
than 10% of mature adipocytes are renewed each year in
subcutaneous adipose tissue (29), cell hyperplasia may
represent a long-term adipose tissue adaptation to face
excess energy intake. Conversely, the predominance of cell
hypertrophy in visceral adipose tissue may suggest that it is
a short-term storage compartment. Increased adipose tissue
storage capacity through peroxisome proliferator–activated
receptor-g agonist–induced hyperplasia has been shown to
promote fat redistribution and to reduce visceral fat accu-
mulation (30). These observations show that increasing
adipogenic capacity in subcutaneous adipose tissue may
TABLE 4
Multivariate logistic regression analysis for triglyceride greater than 1.69 mmol/L
Independent variables (unit 10%)
Unadjusted Adjusted*
P value OR 95% CI OR 95% CI
Omental adipose tissue depot
Adipocyte size (8.3 mm) 2.08 1.48–3.04 4.06 1.92–9.97 ,0.001
Number of adipocytes (1.7 3 10
5) 1.16 1.03–1.30 1.55 1.12–2.29 ,0.02
Subcutaneous adipose tissue depot
Adipocyte size (9.9 mm) 1.46 0.87–2.53 0.76 0.18–2.81 NS
Number of adipocytes (4.2 3 10
5) 1.05 0.91–1.22 0.72 0.37–1.26 NS
*Logistic regression model was adjusted for body fat mass (NS), subcutaneous adipose tissue area (NS), visceral adipose tissue area (P =
0.07), free fat mass (NS), BMI (NS), age (NS), menopausal status (NS), and hormone replacement therapy (NS); n = 150.
TABLE 3
Characteristics of women matched for visceral adipose tissue
area and subcutaneous adipocyte size but with either small or
large omental adipocytes (n = 54)
Variables
Omental adipocytes
P value Small Large
Anthropometrics
Age (years) 47.1 6 5.7 47.4 6 5.2 NS
BMI (kg/m
2) 28.2 6 6.3 27.2 6 4.8 NS
Fat mass (kg) 28.8 6 10.7 27.6 6 9.1 NS
Body lean mass (kg) 42.0 6 6.7 40.9 6 6.9 NS
Adipose tissue area (cm
2)
Total 446 6 179 431 6 159 NS
Subcutaneous 350 6 147 334 6 123 NS
Visceral 101 6 50 101 6 51 NS
Adipocyte diameter (mm)
Subcutaneous 100.9 6 12.2 100.4 6 10.4 NS
Omental 77.1 6 13.5 93.6 6 13.7 ,0.0001
Number of adipocytes L4-L5 (310
6)
Subcutaneous depots 4.39 6 1.71 4.21 6 1.52 NS
Visceral depots 2.06 6 0.53 1.40 6 0.42 ,0.0001
Lipid proﬁle (mmol/L)
Plasma triglycerides 1.25 6 0.48 1.47 6 0.66 ,0.01
VLDL triglycerides 0.74 6 0.40 0.93 6 0.56 ,0.01
Total cholesterol 5.05 6 0.96 5.13 6 0.98 NS
VLDL cholesterol 0.44 6 0.23 0.55 6 0.37 ,0.05
LDL cholesterol 3.13 6 0.94 3.20 6 0.87 NS
HDL cholesterol 1.48 6 0.36 1.38 6 0.31 0.08
HDL2 cholesterol 0.61 6 0.27 0.53 6 0.20 ,0.05
HDL3 cholesterol 0.87 6 0.18 0.85 6 0.18 NS
Apolipoprotein B (g/L) 0.94 6 0.25 0.99 6 0.26 NS
Total-to-HDL
cholesterol ratio 3.60 6 1.04 3.92 6 1.30 0.07
Glucose homeostatsis
Fasting glucose
(mmol/L)† 5.62 6 0.63 5.86 6 0.64 NS
Fasting insulin
(pmol/L)†† 9.8 6 7.7 10.5 6 5.8 NS
HOMA-IR index††† 2.62 6 2.22 2.85 6 1.71 NS
†n = 46; ††n = 48; †††n = 43.
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Although this study was not designed to investigate the
mechanisms involved in the association of adipocyte hy-
pertrophy and metabolic alterations, several hypotheses
may be put forward. Involvement of visceral, but not
subcutaneous, adipose tissue cellularity could indirectly
reinforce the role of excess free fatty acids (31). Indeed,
previous studies have reported that large adipocytes
showed alterations in lipolysis, insulin sensitivity, and adi-
pokine secretion compared with smaller adipocytes from
the same individual (12,13,15,16). Although visceral adipose
tissue is not believed to be a major source for the circu-
lating free fatty acid pool, the contribution of visceral adi-
pose tissue lipolysis to hepatic free fatty acid delivery is
positively associated to visceral fat accumulation (32). In-
creased responsiveness to b-adrenergic agonist stimulation
(33–35) and decreased sensitivity to insulin suppression of
lipolysis (36,37) in hypertrophic omental adipocytes could
possibly impact splanchnic free fatty acid levels, especially
in the visceral obese. Increased free fatty acid delivery to
the liver was suggested to increased triglyceride-rich VLDL
production, which is associated with small, dense LDL par-
ticles as well as with lower HDL cholesterol levels (38,39).
The altered lipid proﬁle observed in women characterized
by omental adipocyte hypertrophy is, therefore, consistent
with this hypothesis. An altered adipokine secretion pat-
tern, as observed with large adipocytes, may also inﬂuence
local adipose tissue lipid metabolism and generate abnor-
mal adipose-derived signaling through the portal vein (15).
Moreover, reduced cellular stability of large adipocytes may
increase the risk of cell rupture in hypertrophic adipose
tissue (40). Chronic, low-grade inﬂammation provoked by
adipocyte death may then contribute to the metabolic alter-
ations associated with obesity (41).
Results of this study are strengthened by the use
of extensive measures of adiposity and body fat distribu-
tion together with characterization of subcutaneous and
omental adipose tissue cellularity. Moreover, the absence
of differences in body composition and fat distribution
measures between women characterized by hypertrophy
and hyperplasia supports the validity and the strength of
the methodology used. We suggest that this stratiﬁcation is
adequate to assess metabolic alterations associated to
subcutaneous or omental hypertrophy, independent of
body composition and fat distribution. However, some
limitations in the study design should be acknowledged.
The present analyses are based on cross-sectional data,
and it is hazardous to conclude cause-and-effect relation-
ships between visceral adipocyte hypertrophy and the
development of metabolic alterations in women. The dif-
ﬁculty to recruit lean to moderately obese men undergoing
abdominal surgery limits our capacity to perform a com-
parable study in men. Most previous studies (1,3,5,9) in-
cluded both men and women, but only subcutaneous
adipose tissue cellularity was assessed. This study was not
designed to assess the involvement of very small adipo-
cytes in metabolic alterations since we used collagenase-
digested adipose tissue samples. We could neither support
nor challenge the previous report by McLaughlin et al. (42)
suggesting that the proportion of very small adipocytes is
associated with metabolic alterations. Finally, because we
only had access to omental and not mesenteric adipose
tissue, visceral adipocyte numbers were computed using
omental adipocyte surface. We assumed that mean adipocyte
sizes in each visceral adipose tissue depot are strongly
correlated, as previously observed for the subcutaneous
and visceral adipose tissue depots (4).
During the revision process of this article, Hoffstedt
et al. (43) published a similar study reporting that visceral
adipose tissue hypertrophy is associated with dyslipidemia.
Our study is generally concordant with these results. How-
ever, they show that subcutaneous adipocyte hypertrophy
was independently associated with glucose homeostasis.
The recruitment of morbidly obese women and our use of
detailed assessment of body fat distribution may account
for these discrepancies.
In conclusion, our results support the hypothesis that
omental adipose tissue cellularity is an important predictor
of hypertriglyceridemia in women. We demonstrate that
the association between omental adipocyte hypertrophy
and lipid proﬁle alterations is independent of differences in
subcutaneous adipose tissue cellularity, body composition,
and fat distribution in women.
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